在mRNACOVID-19疫苗接种后的吉兰-巴雷综合征:评论
Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2
1Private Academic Consultant, Bangkok Thailand.
Acta neurologica Taiwanica
|October 2, 2023
概括
吉兰-巴雷综合征可能发生在BNT162b2 mRNA COVID-19疫苗接种后,但可治疗. 接种COVID-19疫苗的好处超过了风险,尽管需要进一步研究神经学副作用.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 吉兰-巴雷综合征是一种罕见的神经系统疾病,可由感染引发,在某些情况下,疫苗接种.
- BNT162b2 mRNA COVID-19 疫苗与吉林巴雷综合征的潜在风险有关.
- 了解COVID-19疫苗接种与诸如吉兰-巴雷综合征之类的神经学副作用之间的关系对于公共卫生至关重要.
研究的目的:
- 讨论在BNT162b2 mRNA COVID-19疫苗接种后发生的吉兰-巴雷综合征.
- 要强调,接种疫苗后的吉林巴雷综合征是一种可治疗的疾病.
- 强调继续研究COVID-19疫苗潜在的神经学副作用的重要性.
主要方法:
- 在接种BNT162b2 mRNACOVID-19疫苗后,对Guillain-Barré综合征的病例报告分析.
- 关于COVID-19疫苗副作用和神经系统并发症的文献综述.
- 讨论相关因素,如并发症和遗传学.
主要成果:
- 在接种BNT162b2 mRNA COVID-19疫苗的第一剂后观察到吉兰-巴雷综合征.
- 这项研究表明,接种疫苗后的吉林巴雷综合征是可以管理和治疗的.
- 据认为,COVID-19疫苗接种的整体好处超过了潜在的风险.
结论:
- 意识到COVID-19疫苗接种后可能产生的神经系统副作用,如吉兰-巴雷综合征,很重要.
- 需要进一步的研究,以充分了解影响疫苗诱导的神经疾病的潜在机制和遗传因素.
- 持续的监测和研究对于确保疫苗的安全性和有效性至关重要.
更多相关视频
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
11.5K
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022
3.6K
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Cross-reactivity
31.2K
Overview
31.2K
Myasthenia Gravis: Diagnostic Tests
960
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
960
Vaccinations
44.6K
Overview
44.6K
Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Leaky Scanning
5.2K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K
